• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Galkin Vladimir bought $2,469,387 worth of shares (346,736 units at $7.12) and sold $1,879,632 worth of shares (258,483 units at $7.27) (SEC Form 4)

    9/24/24 12:00:28 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care
    Get the next $LUCY alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Galkin Vladimir

    (Last) (First) (Middle)
    10900 NW 97TH STREET, #102

    (Street)
    MIAMI FL 33178

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Innovative Eyewear Inc [ LUCY ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/17/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.00001 09/17/2024 P 67,164 A $7.77(1)(2) 398,911 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 P 2,841 A $7.65(1)(4) 401,752 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 P 66,835 A $7.44(1)(5) 468,587 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 P 169,903 A $6.85(1)(6) 638,490 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 P 36,478 A $6.66(1)(7) 674,968 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 P 3,515 A $6.19(1)(8) 678,483 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 S 51,656 D $8.1(1)(9) 626,827 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 S 40,387 D $8(1)(10) 586,440 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 S 134,693 D $6.88(1)(11) 451,747 I See footnote(3)
    Common Stock, par value $0.00001 09/17/2024 S 31,747 D $6.66(1)(12) 420,000 I See footnote(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported reflects the volume weighted average purchase or sale price (whichever the case may be) on the transaction date within a $0.25 range, unless otherwise noted. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price within the ranges set forth in footnotes (2) and (4) to (12) in this Form 4.
    2. The purchases were executed in multiple trades at a price of $7.77.
    3. The Angelica Galkin Revocable Trust, dated April 21, 2018 ("Galkin Revocable Trust") directly holds the shares of Common Stock. Angelica Galkin is the sole trustee and beneficiary of the Galkin Revocable Trust. Angelica Galkin has delegated to Vladimir Galkin the shared right to direct the voting and disposition of the securities owned by the Galkin Revocable Trust. Accordingly, each of Vladimir Galkin and Angelica Galkin may be deemed to beneficially own the securities owned directly by Galkin Revocable Trust. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") or for any other purpose.
    4. The purchases were executed in multiple trades at prices ranging from $7.55 to $7.74.
    5. The purchases were executed in multiple trades at prices ranging from $7.40 to $7.50.
    6. The purchases were executed in multiple trades at prices ranging from $6.77 to $6.88.
    7. The purchases were executed in multiple trades at prices ranging from $6.54 to $6.73.
    8. The purchases were executed in multiple trades at prices ranging from $6.00 to $$6.22.
    9. The sales were executed in multiple trades at prices ranging from $8.01 to $8.10.
    10. The sales were executed in multiple trades at a price of $8.00.
    11. The sales were executed in multiple trades at prices ranging from $6.77 to $7.00.
    12. The sales were executed in multiple trades at a price of $6.66.
    /s/ Vladimir Galkin, Attorney in Fact 09/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LUCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUCY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LUCY
    Financials

    Live finance-specific insights

    See more
    • Innovative Eyewear Inc. Reports Third Quarter 2024 Financial Results

      Revenue Increased 14% in Q3 2024 vs Q3 2023, and 76% on a Year-to-Date Basis vs 2023 MIAMI, Nov. 13, 2024 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), a developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced its financial results for the third quarter of 2024. Net revenue for the quarter ended September 30, 2024 was $253,599, an increase of 14% from the quarter ended September 30, 2023. This year-over-year increase was primarily attributable to strategic reductions in price discounts and other adjustments to o

      11/13/24 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear, Inc. Adopts Limited Duration Stockholders Rights Plan

      MIAMI, Sept. 25, 2024 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (Nasdaq: LUCY), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one right ("Right") for each outstanding share of common stock. The record date for such dividend distribution is September 25, 2024. The Rights Plan expires, without any further action being required to be taken by Innovative Eyewear's Board of Directors, on September 25, 2025 or at such earlier time as disclos

      9/25/24 8:20:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear Inc. Reports Second Quarter 2024 Financial Results

      Quarterly Revenue Increased 82% vs Q2 2023; Gross Margin Increases Substantially MIAMI, Aug. 13, 2024 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW))), the developer of ChatGPT-enabled smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced its financial results for the second quarter of 2024. Net revenue for the quarter ended June 30, 2024 was $308,682, an increase of 82% from the quarter ended June 30, 2023. Net revenue for the six months ended June 30, 2024 was $692,153, an increase of 120% vs. the comparable period in 2023.

      8/13/24 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Gayle Oswald

      3 - Innovative Eyewear Inc (0001808377) (Issuer)

      10/25/24 9:59:55 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $721,472 worth of shares (70,000 units at $10.31) and sold $148,896 worth of shares (14,037 units at $10.61) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 4:12:34 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $1,822,973 worth of shares (200,792 units at $9.08) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 2:41:40 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Innovative Eyewear Inc.

      10-Q - Innovative Eyewear Inc (0001808377) (Filer)

      5/13/25 4:30:26 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • SEC Form S-1 filed by Innovative Eyewear Inc.

      S-1 - Innovative Eyewear Inc (0001808377) (Filer)

      5/9/25 4:05:44 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • SEC Form SCHEDULE 13G filed by Innovative Eyewear Inc.

      SCHEDULE 13G - Innovative Eyewear Inc (0001808377) (Subject)

      4/17/25 4:04:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Innovative Eyewear Inc.

      SC 13G/A - Innovative Eyewear Inc (0001808377) (Subject)

      11/13/24 11:18:48 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Innovative Eyewear Inc.

      SC 13D/A - Innovative Eyewear Inc (0001808377) (Subject)

      10/4/24 4:43:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Innovative Eyewear Inc.

      SC 13D/A - Innovative Eyewear Inc (0001808377) (Subject)

      9/25/24 4:17:38 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Galkin Vladimir bought $721,472 worth of shares (70,000 units at $10.31) and sold $148,896 worth of shares (14,037 units at $10.61) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 4:12:34 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $1,822,973 worth of shares (200,792 units at $9.08) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 2:41:40 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Amendment: Large owner Galkin Vladimir bought $2,649,148 worth of shares (297,443 units at $8.91) and sold $384,100 worth of shares (42,328 units at $9.07) (SEC Form 4)

      4/A - Innovative Eyewear Inc (0001808377) (Issuer)

      9/27/24 2:40:55 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Innovative Eyewear Inc. Reports Q1 2025 Unaudited Financial Results

      Revenue and gross margins improvements MIAMI, May 13, 2025 /PRNewswire/ -- Innovative Eyewear Inc., (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced its Q1 2025 Unaudited financial results. Net revenue for the quarter ended March 31, 2025 was $454,501 an increase of 19% from revenue of $383,471 in the quarter ended March 31, 2024. This increase was primarily attributable to growth in unit sales volume, largely driven by product launches during 2024 of the co-branded Nautica® Powered by Lucyd and

      5/13/25 5:49:00 PM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear Partners with Eye Recommend, Expanding Smart Eyewear Access Across 600+ Independent Optometry Stores

      MIAMI, May 5, 2025 /PRNewswire/ -- Innovative Eyewear, Inc. (NASDAQ:LUCY, LUCYW)), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announces that it has partnered with Eye Recommend to provide its smart eyewear to more than 600 independent optical practices across Canada, significantly broadening accessibility of Innovative Eyewear's smart eyewear throughout the Canadian market. Buying groups like Eye Recommend serve an important function in the optical industry landscape, making it easier for independent optometrists to access

      5/5/25 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care
    • Innovative Eyewear Launches Reebok® Smart Eyewear

      MIAMI, April 28, 2025 /PRNewswire/ -- Innovative Eyewear Inc. (NASDAQ:LUCY), the developer of smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, today announced the launch of Reebok Smart Eyewear, available worldwide on Lucyd.co. Expanded availability is expected later this quarter on Reebok.com and select online and traditional retailers. A Landmark Product Launch The global smart glasses market is projected to reach approximately $13 billion worldwide by 20301. We believe Reebok Powered by Lucyd smart eyewear positions Innovative Eyewear at the forefr

      4/28/25 8:00:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care

    $LUCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Innovative Eyewear, Inc. Signs Professional Football Player Emmanuel Ogbah as Brand Ambassador

      MIAMI, Dec. 14, 2023 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ:LUCY, LUCYW))), the developer of the developer of ChatGPT smart eyewear under the Lucyd®, Nautica®, Eddie Bauer® and Reebok® brands, is pleased to announce the signing of Emmanuel Ogbah as an official brand ambassador. Emmanuel Ikechukwu Ogbah is a Nigerian professional football defensive end for the Miami Dolphins. He played college football at Oklahoma State and was drafted by the Cleveland Browns in the second round of the 2016 NFL Draft. Lucyd eyewear's open-ear au

      12/14/23 8:30:00 AM ET
      $LUCY
      Ophthalmic Goods
      Health Care